Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493027 | 0.91 | MCL1 (0.43) | MRGPRX4PIK3C2B | |
| SCHEMBL6491233 | 0.91 | MRGPRX4 (0.40) | FABP3FABP4FABP5PTGER1MRGPRX4 | |
| SCHEMBL6498814 | 0.90 | S1PR1 (0.39) | PIK3C2B | |
| SCHEMBL7200058 | 0.89 | FABP3 (0.48) | FABP3FABP4FABP5PTGER1MRGPRX4 | |
| SCHEMBL6495987 | 0.88 | PIK3C2B (0.41) | FABP3FABP4FABP5PTGER1MRGPRX4 | |
| SCHEMBL6488028 | 0.84 | AGTR1 (0.40) | MRGPRX4SMN1; SMN2 | |
| SCHEMBL6501562 | 0.83 | NR4A2 (0.57) | MRGPRX4ALOX5AP | |
| SCHEMBL6498704 | 0.83 | P2RX3 (0.45) | PTGER1MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL7200216 | 0.83 | PIK3C2B (0.41) | FABP3FABP4FABP5PTGER1MRGPRX4 | |
| SCHEMBL6500552 | 0.83 | MRGPRX4 (0.49) | FABP3FABP4FABP5PTGER1MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | FABP3 531/4885FABP4 230/4885FABP5 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.